Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant pazopanib versus placebo after surgery for stage I non-small cell lung cancer
2008-004897-41Phase 2Terminated
- Sponsor
- IFCT
- Start
- Oct 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Pazopanib with Placebo (2 arms). Primary endpoints: Compliance and Disease-free survival. Started Oct 2008; status: terminated.
02
Drugs
pazopanib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2008-004897-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-004897-41.